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from these 13 cohort studies. The 13 studies pooled by Kapoor
et al2 included both 10 cohorts of “noncardiac surgery” and three
cohorts of “cardiac surgery.” The pooled OR from the 10 studies
of “noncardiac surgery” was 0.70 (95% CI, 0.53 to 0.91). Further-
more, these 10 cohorts of “noncardiac surgery” included six
studies of “major (noncarotid) vascular, noncardiac surgery” (eg,
repair of abdominal aortic aneurysm, aorto-femoral bypass, and
infrainguinal revascularization), two studies of “carotid endarter-
ectomy,” one study of both “carotid endarterectomy” and “major
(noncarotid) vascular, noncardiac surgery,” and one study of “tho-
racic surgery.”
We combined the data from the above-mentioned homoge-
nous six cohort studies3-8 of “major (noncarotid) vascular, noncar-
diac surgery” (380 events in 4865 patients) using a random-effects
model, which gave a summary OR of 0.74 (95% CI, 0.54 to 1.01;
P  .0590) with statin use. There was neither trial heterogeneity of
results analyzed by means of standard 2 tests (P  .2602) nor
evidence of significant publication bias assessed using an adjusted
rank-correlation test (P  .8510). Therefore, routine administra-
tion of statins does not reduce perioperative cardiovascular risk in
“major (noncarotid) vascular, noncardiac surgery.”
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Reply
We appreciate the interest of Dr Takagi and colleagues regard-
ing our publication “Statins for the prevention of perioperative
cardiovascular complications in vascular surgery”.
First, we would like to point out that the only double blind
randomized trial published so far that specifically investigated the
effect of statins on perioperative cardiovascular outcome showed a
significant beneficial effect of perioperative statin use (8% vs 26%
cardiovascular complications, P  .03).1
Second, why did Dr Takagi and colleagues only use six retro-
spective studies for their analysis? We agree that including studies
reporting on carotid surgery only2 in their systematic review would
be incorrect. However, the study by O’Neil-Callahan et al3 should
have been included in their review since this study included 177
aortic and 622 lower extremity arterial surgical procedures. If these
799 patients would have been added to the analysis of Takagi and
colleagues, the odds ratio would be 0.71 with 95% confidence
intervals of 0.57 to 0.88 and P for homogeneity of .313. This
suggests a beta-II error of the presented analysis by Dr Takagi. If all
appropriate studies were taken into account, statins would have
provided a highly significant beneficial effect on postoperative
outcome in patients undergoing major vascular surgery.
Third, current American College of Cardiology/American
Heart Association (ACC/AHA) treatment guidelines recommend
statin use for patients at increased cardiovascular risk.4 In fact these
guidelines have as a class 1 recommendation “treatment with a
hydroxymethyl glutaryl coenzyme-A reductase inhibitor medica-
tion is indicated for all patients with peripheral arterial disease to
achieve a target low-density lipoprotein (LDL) cholesterol level of
less than 100 mg per dl.” As all patients scheduled for major
vascular surgery have peripheral arterial disease, it would be pru-
dent to install treatment at the first vascular surgery outpatient
clinic visit. In particular, since current evidence does suggest that
there is no increased risk for myopathy or rhabdomyolysis in
patients on statin therapy undergoing major vascular surgery.5
In conclusion, if a proper meta-analysis of all cohort studies
reporting on cardiac outcome in statin or nonstatin users under-
going major vascular surgery is performed, the results show a
highly significant beneficial effect of statins. This result is sup-
ported by the only double blind randomized trial published on this
subject to date. Consequently, we still believe that routine admin-
istration of statins in patients undergoing major vascular surgery
reduces perioperative cardiovascular risk.
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Regarding “Elevated C-reactive protein levels are
associated with postoperative events in patients
undergoing lower extremity vein bypass surgery”
Owens et al1 have reported the results of a prospective study
on the prognostic significance of C-reactive protein (CRP) in
patients undergoing lower extremity vein bypass surgery. They
stated that this is the first study demonstrating the role of this
inflammatory marker on the outcome of patients with lower limb
ischemia.
Indeed, about 15 years ago, Majewski et al were the first to
suggest the prognostic value of CRP in patients with chronic2 as
well as acute lower limb ischemia.3 The latter findings were nicely
confirmed by Kuukasjärvi et al.4 More important, Upchurch et al5
were the first to demonstrate a clear correlation between CRP and
the severity of foot ulcers.
This prompted us to investigate this issue in patients under-
going infrainguinal bypass surgery.6-8 These studies showed
that CRP not only was clearly correlated with the severity of
lower limb ischemia but also with infection due to some
bacterial strains.6 CRP came out as one of the most impor-
tant determinants of several postoperative outcome end
points.
However, these findings, as well as the extremely elevated
levels of CRP in patients with critical limb ischemia, suggest that
CRP cannot be considered as a marker aggressive atherosclero-
sis, but rather as a marker of the severity of lower limb athero-
sclerosis and its related ischemic complications. This also sug-
gests that in these patients, CRP is not likely to be a major
determinant of vein graft disease but rather that increased CRP
is associated with severe critical limb ischemia and with other
extrinsic determinants of graft failure. Interestingly, preopera-
tive levels of CRP were markedly increased, especially in those
patients who required lower limb amputation despite a patent
graft.7,8
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Reply
We appreciate the interest and concerns of the correspondents
regarding our article “Elevated C-Reactive Protein Levels Are
Associated With Postoperative Events in Patients Undergoing
Lower Extremity Vein Bypass Surgery.” As they point out, a
number of authors have previously demonstrated an association
between C-reactive protein (CRP) levels and the severity of periph-
eral arterial disease, including complications related to critical limb
ischemia; our results are but another confirmation in this regard.
These studies vary in the heterogeneity of the study populations
and, importantly, in the use of the current high-sensitivity assay
(hsCRP) used in these studies. However, the unique focus of our
investigation was to examine the relevance of inflammatory bi-
omarkers such as hsCRP to the outcomes of vein bypass surgery in
the limb.
As stated in the introduction, our hypothesis is that chronic,
low-grade, systemic inflammation is directly related to the devel-
opment and progression of vein graft disease.1 CRP is increased in
acute infection, cancer, and systemic illness, and it is associated
with diabetes, renal failure, and critical limb ischemia. We did not
intend to measure the effects of acute increases in CRP attendant
with severe infections or extensive necrosis. Accordingly, our study
design specifically excluded patients who had evidence of clinical
infection, immunocompromised states, or systemic illness such as
recent myocardial infarction.1 The median hsCRP concentration
in our study population was 3.25 mg/L. By contrast, the other
cited studies2-4 included reconstruction procedures with mixed
conduits, including prosthetic, and were not designed to evaluate
associations with failure of autogenous conduits.2-4 More impor-
tantly, the study populations seem significantly different from ours
in terms of the inclusion of patients with severe, acute inflamma-
tion. For example, in the referenced studies, the median CRP in
patients having an amputation was greater than 40 mg/L and was
greater than 100 mg/L in those having an amputation despite an
open graft; these values are an order of magnitude larger than those
observed in our cohort.2-4 These authors concluded that patients
undergoing pedal bypass who have a CRP greater than 100 mg/L
have a twofold risk for limb loss at 1 year.2 Although lacking an
explicitly stated hypothesis,2,3 it seems likely these studies evaluate
CRP as a biochemical surrogate for the degree of lower extremity
tissue loss and/or infection, which might then influence limb
salvage by failures not specific to revascularization.
In our published article, we reported that among a cohort of
91 patients undergoing autogenous vein reconstruction, a baseline
level of hsCRP greater than 5 mg/L (the upper reference level in
our laboratory) was predictive of subsequent major cardiovascular
events, the majority of which were vein graft related.1 This rela-
tionship was maintained on multivariate analysis when confound-
ing factors were controlled. In an updated analysis that included
more patients (n 147) and additional observation time, patients
with elevated baseline hsCRP (5 mg/L) experienced more vein
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